customisable counter
 
Trovagene, disease areas, applications, human, in-vitro, proof of principle, oncology, CTC, blood test, imaging, mutation, cancer, K-RAS, cancers, pre-natal screening, sequencing, disorders, aneuploidies, monogenic, TROV.pk, investors, invest, investment, stock, price, share, information, news, press room, events, IR, investor relations, services, San Diego, lab, laboratory, operations, clinical, applications, alien, prenatal, testing, metastatic, pregnancy, diagnosism, pathogens, tumor, therapies, analysis, trans-renal, genetic, information, kidney, circulating, technology, license, licensing opportunities, science, platform, research, development, R&D, pipeline, TROV, DNA, RNA, molecular, diagnostics, urine, test, detection, cancer, medicine, nucleic acid, infection, revolution, disease, personalized medicine, non-invasive, CLIA, markers

Trovagene, INC.  |  TROV.PK

Trovagene, disease areas, applications, human, in-vitro, proof of principle, oncology, CTC, blood test, imaging, mutation, cancer, K-RAS, cancers, pre-natal screening, sequencing, disorders, aneuploidies, monogenic, TROV.pk, investors, invest, investment, stock, price, share, information, news, press room, events, IR, investor relations, services, San Diego, lab, laboratory, operations, clinical, applications, alien, prenatal, testing, metastatic, pregnancy, diagnosism, pathogens, tumor, therapies, analysis, trans-renal, genetic, information, kidney, circulating, technology, license, licensing opportunities, science, platform, research, development, R&D, pipeline, TROV, DNA, RNA, molecular, diagnostics, urine, test, detection, cancer, medicine, nucleic acid, infection, revolution, disease, personalized medicine, non-invasive, CLIA, markers

About Us

Services

Technology

Disease Areas

News & Events

Contact Us

 

Rapid Industry Sector Growth


Perfect Timing for Next Generation Urine-based Testing

THE GLOBAL MOLECULAR DIAGNOSTICS MARKET

  1. ‣Total market

  2. -$20.1 billion in 2013

  3. -CAGR of 13.7%

  4. ‣PCR-based diagnostic assays still the largest share

  5. -$9.5 billion in 2013

  6. -CAGR of 11.9%.

  7. ‣Lab-on-a-chip (micro-fluidics) is fastest growing  segment

  8. -$2.1 billion in 2013

  9. -CAGR of 18.7%.

 

  1. ‣Introduction

  2. ‣Oncology

  3. ‣Pre-Natal Screening

  4. ‣Infection

Introduction to our Disease Area Focus

Trovagene is developing a transrenal molecular diagnostic assay platform ideal for human in-vitro diagnostic testing.  Proof of principle experiments have been completed for each of four major clinical applications: cancer detection and monitoring, infectious disease testing, organ transplant rejection monitoring and non-invasive prenatal genetic testing.

Broad Clinical Utility

Discovery of TR-DNA creates the basis for development of new tests in molecular diagnostic assays with broad clinical utility in a variety of disease areas. Our early focus areas include prenatal genetic testing, oncology, infectious diseases, organ transplantation, and others. Quantitative measurement of specific marker concentrations can be used for disease monitoring.

Tumor markers

  1. ‣Colon and pancreatic cancers (K-ras)

  2. ‣Nasopharyngeal carcinoma

  3. ‣Cervical cancer

Find out more »

Fetal DNA markers: Truly Non-invasive Screening of Pre-natal Disorders

  1. ‣In maternal urine for aneuploidy screening

Find out more »

Pathogens

  1. ‣Viruses: HPV, HIV, EBV, JC 

  2. ‣Bacteria: Mycobacterium tuberculosis, Helicobacter pylori, Bacillus anthracis

  3. ‣Parasites: Leishmania, Plasmodium

Find out more »

Transplantation markers

Trovagene, disease areas, applications, human, in-vitro, proof of principle, oncology, CTC, blood test, imaging, mutation, cancer, K-RAS, cancers, pre-natal screening, sequencing, disorders, aneuploidies, monogenic, TROV.pk, investors, invest, investment, stock, price, share, information, news, press room, events, IR, investor relations, services, San Diego, lab, laboratory, operations, clinical, applications, alien, prenatal, testing, metastatic, pregnancy, diagnosism, pathogens, tumor, therapies, analysis, trans-renal, genetic, information, kidney, circulating, technology, license, licensing opportunities, science, platform, research, development, R&D, pipeline, TROV, DNA, RNA, molecular, diagnostics, urine, test, detection, cancer, medicine, nucleic acid, infection, revolution, disease, personalized medicine, non-invasive, CLIA, markers